Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Novartis AG ADR (NVS-RMDR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Novartis ADR historical data, for real-time data please try another search
6,323.00 0.00    0.00%
24/02 - Real-time Data. Currency in RUB ( Disclaimer )
Type:  Equity
Market:  Russia
ISIN:  US66987V1098 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 6,323.00 - 7,012.00
Novartis ADR 6,323.00 0.00 0.00%

NVS-RMDR Balance Sheet

 
Featured here, the Balance Sheet for Novartis AG ADR, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 30481 45660 33493 32114
Cash and Short Term Investments 14073 12816 11072 12187
Cash - - - -
Cash & Equivalents 13393 12405 10885 12000
Short Term Investments 680 411 187 187
Total Receivables, Net 9247 7099 9543 9183
Accounts Receivables - Trade, Net 7107 6819 9195 8916
Total Inventory 5913 5610 8228 7886
Prepaid Expenses 764 - - -
Other Current Assets, Total 484 20135 4650 2858
Total Assets 99945 112697 110979 112241
Property/Plant/Equipment, Total - Net 10924 10344 12277 12348
Property/Plant/Equipment, Total - Gross 22803 - - -
Accumulated Depreciation, Total -11879 - - -
Goodwill, Net 23341 23416 29522 29481
Intangibles, Net 26879 26418 28003 30451
Long Term Investments 1827 1530 1758 1788
Note Receivable - Long Term 2140 280 348 267
Other Long Term Assets, Total 1966 1701 1883 1978
Other Assets, Total 2357 22685 7565 5829
Total Current Liabilities 26390 48393 31909 30549
Accounts Payable 4926 3870 5350 5426
Payable/Accrued - - - -
Accrued Expenses 5174 - - -
Notes Payable/Short Term Debt 3893 - - -
Current Port. of LT Debt/Capital Leases 2512 5668 8536 7219
Other Current liabilities, Total 9885 38855 18023 17904
Total Liabilities 53195 74452 59048 60099
Total Long Term Debt 20034 19521 19804 21985
Long Term Debt 18436 18068 18259 20396
Capital Lease Obligations 1598 1453 1545 1589
Deferred Income Tax 2248 2457 2526 2727
Minority Interest 83 81 84 83
Other Liabilities, Total -119 2993 3718 3748
Total Equity 46750 38245 51931 52142
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 825 825 842 842
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) 49649 42333 55682 56089
Treasury Stock - Common -41 -32 -52 -36
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -3683 -4881 -4541 -4753
Total Liabilities & Shareholders' Equity 99945 112697 110979 112241
Total Common Shares Outstanding 2044.03 2055.46 2068.26 2097.4
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVS Comments

Write your thoughts about Novartis AG DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jonah Garber
Jonah Garber Aug 03, 2022 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVS reported solid results for Q1 that included a 10% jump in sales for its top-selling Cosentyx psoriatic arthritis drug. With a diverse portfolio of pharmaceuticals and strong momentum in a down market, NVS is worth a look for many reasons
Jonathan Sanders
Jonathan Sanders Aug 03, 2022 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks in part to strong performance, this is one of a few stocks that has posted positive gains in 2022 despite headwinds elsewhere in the market.
Zoran Labus
Zoran Labus Mar 25, 2021 11:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Pankaj Negi
Pankaj Negi Jan 20, 2021 1:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
Pete Pete
Pete Pete Sep 30, 2020 12:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
stats con chris
stats con chris Jun 17, 2020 12:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just to know. I'm lost.this is the company that bought the medicines company?
Kristof Mouton
Stoffel Sep 17, 2019 4:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
before investing in @novartis, read #teampia (twitter).
Kas Kas
KastKast Feb 07, 2019 2:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
154952291883003.jpg
sell 89 expecting 80 timeframe 5 days
Robin Hood
Robin Hood Sep 28, 2018 7:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long ENDOCYTE... I work in the field
Episcopolian OptionTrader
Episcopolian1 Jul 19, 2017 11:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email